摘要
目的:探讨新辅助化疗分别在Ⅱ期和Ⅲ期乳腺癌中的应用价值。方法:选取1994年9月～1999年9月术前经病理确诊可手术乳腺癌426例,分为新辅助化疗组(A组)和对照组(B组)。分析两组的术式选择、局部控制和5年生存率,评价新辅助化疗在Ⅱ、Ⅲ期乳腺癌治疗中的价值。结果:Ⅱ期可保乳率由24.7%提高到44.6%(P=0.000),两组5年总生存率(OS)和无瘤生存率(DFS)无差异(P=0.525、0.581)。Ⅲ期A组患者5年OS和DFS(62.9%、58.1%)均高于B组(39.5%、32.6%)(P=0.014、0.010)。Ⅱ、Ⅲ期化疗后需植皮术均下降(P=0.000、0.000),3年内复发转移A组均低于B组(P=0.035、0.027)。结论:新辅助化疗可提高Ⅱ、Ⅲ期可手术乳腺癌患者的保乳率、减少植皮术、降低局部复发转移;可提高Ⅲ期乳腺癌患者的5年生存率。
To evaluate the therapeutic value of neoadjuvant chemotherapy for patients with stage Ⅱ and Ⅲ breast cancer. Methods： A total of 26 breast cancers patients at stage Ⅱ and Ⅲ, pathologieally proven during September 1994 to September 1999, were studied, which were divided into neoadjuvant chemotherapy group （A） and control group （B）. The impact of neoadjuvant chemotherapy on surgical methods choice, local control rate, 5-year overall survival rate （OS） and 5-year diseasefree survival rate （DFS） were analyzed and the therapeutic value of neoadjuvant chemotherapy on the breast cancer patients at stage Ⅱ and Ⅲ were discussed. Results： For patients of stage Ⅱ, the rate of breast conservation significantly increased from 24.7% to 44.6% （P=0.000） and there was no significant difference between group A and B （P=0.525, 0.581） in 5-year OS and DFS. For patients of stage Ⅲ, the 5-year OS （62.9%） and DFS（58.1%） in group A were greatly higher than that in group B （39.5% and 32.6%） （P=0.014, 0.010）. The imperative dermatoplasty rate of the breast cancer patients at stage Ⅱ and Ⅲ in Group A decrease greatly （P=0.000、0.000） and the 3-year local relapse and metastasis rate were lower than group B （P=0.035,0.027）. Conclusion： The neoadjuvant chemotherapy can improve potential rate of hreast conservation, reduce the rate of imperative dermatoplasty, local-regional recurrence rate and distant metastasis for the patients with stage Ⅱ and Ⅲ breast cancer, and can, also improve the 5-year survival rule for the patients of stage Ⅲ .
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2005年第22期1293-1295,共3页
Chinese Journal of Clinical Oncology
关键词
乳腺癌
新辅助化疗
5年生存率
术式选择
Breast cancer Neoadjuvant chemotherapy Choice of surgical methods 5-year survival rate
